These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24267260)

  • 1. Quantitative and qualitative pleiotropic differences between Simvastatin single and Vytorin combination therapy in hypercholesterolemic subjects.
    Sternberg Z; Chichelli T; Sternberg D; Hojnacki D; Drake A; Liu S; Hu Q; Munschauer F
    Atherosclerosis; 2013 Dec; 231(2):411-20. PubMed ID: 24267260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
    Ballantyne CM; Abate N; Yuan Z; King TR; Palmisano J
    Am Heart J; 2005 Mar; 149(3):464-73. PubMed ID: 15864235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identical LDL-cholesterol lowering but non-identical effects on NF-κB activity: High dose simvastatin vs combination therapy with ezetimibe.
    Rudofsky G; Reismann P; Groener JB; Djuric Z; Fleming T; Metzner C; Grafe IA; Bierhaus A; Nawroth PP
    Atherosclerosis; 2012 Jul; 223(1):190-6. PubMed ID: 22633472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
    Abel T; Fehér J; Dinya E; Eldin MG; Kovács A
    Med Sci Monit; 2009 Dec; 15(12):MS6-11. PubMed ID: 19946244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of adhesion molecules by cholesterol-lowering therapy in mononuclear cells from hypercholesterolemic patients.
    Cerda A; Rodrigues AC; Alves C; Genvigir FD; Fajardo CM; Dorea EL; Gusukuma MC; Pinto GA; Hirata MH; Hirata RD
    Cardiovasc Ther; 2015 Aug; 33(4):168-76. PubMed ID: 25903419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia.
    Moutzouri E; Liberopoulos EN; Tellis CC; Milionis HJ; Tselepis AD; Elisaf MS
    Atherosclerosis; 2013 Nov; 231(1):8-14. PubMed ID: 24125402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction.
    Toth PP; Ballantyne CM; Davidson MH; Tomassini JE; Ramey DR; Neff D; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2012; 6(2):180-91. PubMed ID: 22385552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event.
    Brudi P; Reckless JP; Henry DP; Pomykaj T; Lim ST; Massaad R; Vandormael K; Johnson-Levonas AO
    Cardiology; 2009; 113(2):89-97. PubMed ID: 19018143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
    Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D
    Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
    Ballantyne CM; Hoogeveen RC; Raya JL; Cain VA; Palmer MK; Karlson BW;
    Atherosclerosis; 2014 Jan; 232(1):86-93. PubMed ID: 24401221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Begin with the real-world patients of non-goal-achieved hypercholesterolemia in taiwan through the ezetimibe/simvastatin tablet - The BRAVO Study.
    Huang JC; Lee TY; Liou MJ; Lin CM; Pei D; Chen ZC; Liu RT; Kwok CF
    Curr Med Res Opin; 2011 Aug; 27(8):1645-51. PubMed ID: 21699369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.
    Cannon CP; Giugliano RP; Blazing MA; Harrington RA; Peterson JL; Sisk CM; Strony J; Musliner TA; McCabe CH; Veltri E; Braunwald E; Califf RM;
    Am Heart J; 2008 Nov; 156(5):826-32. PubMed ID: 19061694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of simvastatin or its combination with ezetimibe on Toll-like receptor expression and lipopolysaccharide - induced cytokine production in monocytes of hypercholesterolemic patients.
    Moutzouri E; Tellis CC; Rousouli K; Liberopoulos EN; Milionis HJ; Elisaf MS; Tselepis AD
    Atherosclerosis; 2012 Dec; 225(2):381-7. PubMed ID: 23062767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.